We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of people living with HIV.
Reducing the time between contracting HIV and being diagnosed and starting treatment is key to ending the epidemic, this study finds.
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
"We're very much putting the patient in the driver's seat," said Heather Alt, deputy director of nursing with Whitman-Walker. "If folks didn't feel ready, we would not push them to start."
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
May 16, 2019: The dwindling value of baseline genotype testing; severe insomnia and cardiovascular disease; cardiovascular risk stratified by sex among people over 50; the persistence of racial disparities among women diagnosed with HIV.
May 9, 2019: HIV care retention and viral suppression among transgender women; heating opioid use equipment to curb HIV transmission; managing HIV outbreaks among people who are homeless; improving viral suppression among people who use substances.
Sixteen years after the success of Project START for HIV risk reduction, we still don't know what works best for helping people with HIV stay in care after prison.
On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.
Researchers found that people taking common combinations of HIV drugs had increases in weight and body mass index, and those who were relatively thin or older prior to starting therapy were most likely to gain weight.